Bladder (San Francisco, Calif.)最新文献

{"title":"Connexins 43 and 45 hemichannels mediate ATP release in the urinary bladder.","authors":"Hafiz Sana-Ur-Rehman, Irit Markus, Gila Moalem-Taylor, Kate H Moore, Kylie J Mansfield, Lu Liu","doi":"10.14440/bladder.0125","DOIUrl":"10.14440/bladder.0125","url":null,"abstract":"<p><strong>Background: </strong>Connexin (Cx) proteins form gap junctions between adjacent cells to facilitate intercellular communication and also assemble into hemichannels that release small molecules, including adenosine triphosphate (ATP), into the extracellular microenvironment, where ATP acts on purinergic receptors.</p><p><strong>Objective: </strong>This study investigated the roles of Cx43 and Cx45 as ATP release channels in the urinary bladder.</p><p><strong>Methods: </strong>Porcine bladder tissues and cultured cells were stained for Cx43 and Cx45 using immunofluorescence. Cx43- and Cx45-mediated ATP release in response to hypotonic stretch and extracellular Ca²⁺ depletion was assessed in porcine urothelial, suburothelial, and detrusor muscle cells, as well as in the human RT4 cell line.</p><p><strong>Results: </strong>The expression of Cx43 and Cx45 was Immunohistochemically confirmed in porcine bladder tissue, cultured porcine bladder urothelial cells, suburothelial myofibroblasts, detrusor muscle cells, and the human urothelial RT4 cell line. Hypotonic stretch increased ATP release in all four cell types, with porcine urothelial cells exhibiting a 3.8 ± 1.3-fold and RT4 cells a 2.0 ± 0.5-fold increase relative to control levels. Similarly, depletion of extracellular calcium ions (Ca²⁺) stimulated ATP release from porcine urothelial cells and RT4 cells, yielding 5.4 ± 2.9-fold and 2.4 ± 0.8-fold increases, respectively. Blockade of Cx43 channels with a Cx43 mimetic peptide (peptide 5) and Cx45 channels with a Cx45 mimetic peptide reduced ATP release induced by stretch and Ca²⁺ depletion in porcine urothelial cells by 50% and 67%, respectively. These blockers also reduced ATP release in RT4 cells. The contributions of Cx43 and Cx45 to ATP release were less prominent in suburothelial and detrusor muscle cells compared to urothelial cells.</p><p><strong>Conclusion: </strong>These findings highlighted ATP's role as an autocrine/paracrine signaling molecule acting on purinergic receptors during bladder distension and suggested that Cx hemichannels regulate ATP release through mechanotransduction and Ca²⁺-sensitive pathways, providing new insights into bladder sensory mechanisms.</p>","PeriodicalId":72421,"journal":{"name":"Bladder (San Francisco, Calif.)","volume":"12 3","pages":"e21200056"},"PeriodicalIF":0.0,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic ozone therapy improves the quality of life in patients with bladder pain syndrome.","authors":"Mauro Martinelli, Aldo Glielmo, Maria Rita Licci, Daniele Romanello","doi":"10.14440/bladder.2025.0002","DOIUrl":"10.14440/bladder.2025.0002","url":null,"abstract":"<p><strong>Background: </strong>Bladder pain syndrome (BPS), also known as interstitial cystitis, is a chronic condition characterized by pelvic pain and urinary symptoms that severely impair patients' quality of life (QoL). The current therapeutic options often yield suboptimal results, prompting interest in complementary treatments. Systemic ozone therapy, known for its anti-inflammatory, immunomodulatory, and analgesic effects, may represent a promising adjunctive treatment for BPS.</p><p><strong>Objective: </strong>This study aimed to evaluate the efficacy and safety of systemic ozone therapy in improving the self-perceived QoL in patients with BPS.</p><p><strong>Methods: </strong>The retrospective observational study included 40 patients diagnosed with BPS according to ESSIC criteria. All patients underwent systemic ozone therapy administered through hemotransfusion, following a standardized protocol. Outcomes were assessed using the Short Form (SF)-36 questionnaire for QoL and the Global Response Assessment (GRA) for subjective treatment efficacy. Statistical analyses evaluated changes in SF-36 domain scores and their correlation with GRA results.</p><p><strong>Results: </strong>Patients demonstrated significant improvement across all domains of the SF-36 questionnaire, with the most notable gains observed in physical functioning and mental health. The mean GRA score confirmed patient-perceived effectiveness, showing a strong positive correlation with SF-36 improvements (p<0.05). No adverse events or complications were found during the study.</p><p><strong>Conclusion: </strong>Systemic ozone therapy appears to be a safe and effective complementary treatment for BPS, significantly enhancing patients' QoL across multiple domains. While these findings are promising, randomized controlled trials are needed to validate the results and further explore underlying mechanisms, such as the role of ozone in modulating inflammatory and neural pathways.</p>","PeriodicalId":72421,"journal":{"name":"Bladder (San Francisco, Calif.)","volume":"12 3","pages":"e21200054"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of preoperative computed tomography-urography combined with inflammatory markers in predicting lymph node metastasis in patients undergoing radical cystectomy.","authors":"Kun Yang, Mingxin Jiang, Tianyu Zhang, Yunpeng Fan, Yongde Xu, Lei Wang, Xi Zhu, Zhengguo Ji, Wei Qiu, Lang Feng, Jun Li, Daoxin Zhang, Gangyue Hao, Yinong Niu","doi":"10.14440/bladder.2025.0012","DOIUrl":"10.14440/bladder.2025.0012","url":null,"abstract":"<p><strong>Background: </strong>Lymph node metastasis represents a critical prognostic factor in bladder cancer and significantly influences treatment choice and outcomes.</p><p><strong>Objective: </strong>To evaluate the predictive value of the maximum short-axis diameter of pelvic lymph nodes on preoperative computed tomography-urography (CTU), in combination with inflammatory markers, in the prediction of lymph node metastasis in radical cystectomy (RC) patients.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 210 patients who had received CTU within one month before RC at Beijing Friendship Hospital from January 2016 to December 2023. Upon screening, 174 patients were included and assigned into two groups based on postoperative pathology: i.e., lymph node metastasis group (n = 43) and non-metastasis group (n = 131). The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) were calculated. The maximum short-axis diameter of a lymph node ≥8 mm was considered indicative of metastasis. Receiver operating characteristic (ROC) curve analysis was performed to assess predictive performance, determine optimal cutoffs, and construct a prediction model using multivariate logistic regression.</p><p><strong>Results: </strong>Significant differences (<i>P</i> < 0.05) were observed between groups in clinical T stage, tumor grade, NLR, PLR, MLR, and CTU lymph node diameter. ROC analysis revealed optimal cutoff values for NLR (3.22), PLR (156.4), and MLR (0.62). Multivariate logistic regression identified clinical T stage, CTU lymph node diameter, MLR, and PLR as independent predictors (<i>P <</i> 0.05). The resulting model achieved an area under the curve of 0.847 (95% confidence interval: 0.777 - 0.917).</p><p><strong>Conclusion: </strong>A nomogram incorporating CTU findings, clinical T stage, MLR, and PLR effectively predicts lymph node metastasis in RC patients. However, further multi-center validation is required before clinical implementation.</p>","PeriodicalId":72421,"journal":{"name":"Bladder (San Francisco, Calif.)","volume":"12 3","pages":"e21200055"},"PeriodicalIF":0.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of modified laparoscopic single-position radical nephroureterectomy with bladder cuff resection for upper urinary tract urothelial carcinoma: A single-center retrospective study.","authors":"Fei Wu, Zhen Wang, Liang Sun, Meixia Zhang, Hao Ning, Zhihong Niu, Jiaju Lyu, Dexuan Gao","doi":"10.14440/bladder.2025.0007","DOIUrl":"10.14440/bladder.2025.0007","url":null,"abstract":"<p><strong>Background: </strong>Radical nephroureterectomy (RNU) with bladder cuff excision represents the standard treatment for high-risk upper tract urothelial carcinoma (UTUC).</p><p><strong>Objective: </strong>This study aimed to evaluate the safety, feasibility, and clinical outcomes of a modified laparoscopic single-position RNU plus bladder cuff resection.</p><p><strong>Methods: </strong>This retrospective analysis examined patients diagnosed with UTUC who underwent RNU between May 2022 and July 2024. Participants were divided into three groups: Group A (39 patients) underwent the modified technique, Group B (38 patients) received standard laparoscopic nephroureterectomy with bladder cuff resection, and Group C (27 patients) had laparoscopic nephroureterectomy with an additional lower abdominal incision for bladder cuff resection. We compared baseline characteristics, intraoperative variables, and post-operative outcomes among the groups.</p><p><strong>Results: </strong>A total of 104 patients were included and analyzed. Their baseline characteristics showed no significant differences among groups (<i>p</i>>0.05). Group A experienced a significantly shorter operative time and earlier ureteral catheter removal compared to Groups B and C (<i>p</i><0.05). Intraoperative blood loss, gastrointestinal recovery time, and length of hospital stay were comparable between Groups A and B, but the results in the two groups were more favorable against Group C (<i>p</i><0.05). Follow-up revealed no significant differences in tumor recurrence and metastasis rates across groups (<i>p</i>>0.05).</p><p><strong>Conclusion: </strong>The modified laparoscopic single-position RNU in combination with bladder cuff resection is a safe and effective minimally invasive approach for UTUC, offering advantages like reduced operative time, early catheter removal, and enhanced patient recovery, supporting its broader clinical application.</p>","PeriodicalId":72421,"journal":{"name":"Bladder (San Francisco, Calif.)","volume":"12 3","pages":"e21200049"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental paraganglioma of the urinary bladder: A case series highlighting a rare entity and a urologist's nightmare.","authors":"Yassir Mehmood, Rahul Gupta, Arti Mahajan, Yaser Rahman, Kshitij Gupta","doi":"10.14440/bladder.2024.0064","DOIUrl":"10.14440/bladder.2024.0064","url":null,"abstract":"<p><strong>Background: </strong>Pheochromocytomas originate from chromaffin cells of the adrenal medulla, resulting in excessive production of catecholamines and bizarre clinical symptoms. An extra-adrenal pheochromocytoma is called a paraganglioma. Urinary bladder paraganglioma represents an uncommon tumor that accounts for <0.05% of all bladder tumors.</p><p><strong>Case presentation: </strong>Presented here are three cases of incidental urinary bladder paraganglioma, all having hematuria as the primary symptom. During transurethral resection of bladder tumor, blood pressure fluctuated intensely with profuse bleeding, leading to the abandonment of the procedure. The patients were later diagnosed as having paraganglioma, and then, they were subjected to systemic evaluation and definitive treatment.</p><p><strong>Conclusion: </strong>Although bladder paraganglioma is a rare condition, it should be strongly suspected if a patient who has no definitive symptoms of the disease developed a sudden hemodynamic change at the very start of the procedure.</p>","PeriodicalId":72421,"journal":{"name":"Bladder (San Francisco, Calif.)","volume":"12 3","pages":"e21200052"},"PeriodicalIF":0.0,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimally invasive surgical treatments for male lower urinary tract symptoms/benign prostatic enlargement: A review on sexual function outcomes.","authors":"Eric Chung","doi":"10.14440/bladder.2025.0001","DOIUrl":"10.14440/bladder.2025.0001","url":null,"abstract":"<p><strong>Background: </strong>Male lower urinary tract symptoms (LUTS) secondary to benign prostatic enlargement (BPE) represent a common urological condition, especially in older males. Literature supports a strong association between male LUTS/BPE and sexual dysfunction. While transurethral resection of the prostate is often considered the standard for male LUTS/BPE surgical treatment, it causes complications across various male sexual domains, such as erectile dysfunction and ejaculatory disorders. In recent years, there have been considerable advances in minimally invasive surgical treatments (MISTs) for male LUTS/BPE. Published literature has shown that MISTs can improve various parameters of voiding domains while minimizing adverse sexual effects.</p><p><strong>Objective: </strong>This article provides an overview of the present understanding of the association between male LUTS/BPE and sexual dysfunction, and the present commercially available MISTs, with a specific focus on sexual function outcomes.</p><p><strong>Conclusion: </strong>Present MISTs for male LUTS/BPE have demonstrated considerable improvements in various urinary parameters while minimizing adverse effects across different sexual function domains.</p>","PeriodicalId":72421,"journal":{"name":"Bladder (San Francisco, Calif.)","volume":"12 3","pages":"e21200051"},"PeriodicalIF":0.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Applications and future prospects of laser technologies in the treatment of non-muscle invasive bladder cancer.","authors":"Yiting Liu, Lilong Liu, Zhipeng Yao, Yaxin Hou, Zhenghao Liu, Yang Li, Yuhong Ding, Pengjie Shi, Zheng Liu, Ke Chen","doi":"10.14440/bladder.2025.0004","DOIUrl":"10.14440/bladder.2025.0004","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer (BCa) represents a common malignancy of the urinary system across the globe and poses significant treatment challenges.</p><p><strong>Objective: </strong>This review comprehensively examined the application of laser technology in the treatment of BCa, including thulium (Tm) lasers (e.g., Tm-doped yttrium aluminium garnet [YAG]), GreenLight lasers (e.g., potassium titanyl phosphate-doped YAG and lead aluminum borate-doped YAG), holmium lasers (e.g., Ho-doped YAG), Tm fiber laser (TFL), and diode lasers. Studies have demonstrated that laser technology effectively improves tumor resection quality, reduces intraoperative bleeding, shortens recovery time, and lowers recurrence rates. Among these, Ho-doped YAG and Tm-doped YAG lasers have been shown to reduce tissue damage and enhance resection precision, while the TFL has attracted attention for its efficient tissue cutting and minimal thermal damage. GreenLight lasers offer advantages in preserving surrounding healthy tissues and demonstrate potential for use in outpatient settings. Diode lasers, known for their high-energy efficiency, contribute to improved overall treatment efficacy. This article further explored the benefits, drawbacks, and prospective uses of each laser technology in BCa treatment.</p><p><strong>Conclusion: </strong>This article thoroughly reviewed the applications of various laser technologies in BCa treatment, highlight their benefits and limitations, and assess their potential roles in future clinical practice.</p>","PeriodicalId":72421,"journal":{"name":"Bladder (San Francisco, Calif.)","volume":"12 3","pages":"e21200050"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant therapy plus thulium laser transurethral bladder tumor resection for muscle-invasive bladder cancer.","authors":"Honglin Zhong, Wei He, Miao Mo, Shiyu Tong, Yinzhao Wang, Yuhang Wang, Xuhao Liu, Wenhao Zhu, Zhengchao Shen, Zhongfu Huang, Zhenyu Ou, Minfeng Chen","doi":"10.14440/bladder.2024.0065","DOIUrl":"10.14440/bladder.2024.0065","url":null,"abstract":"<p><strong>Background: </strong>Radical cystectomy (RC) is the standard treatment for muscle-invasive bladder cancer (MIBC). However, its high perioperative mortality and significant impact on quality of life have led many patients to opt for bladder-preserving approaches, which currently lack a standardized treatment protocol.</p><p><strong>Objective: </strong>This study evaluated the efficacy and feasibility of bladder-preserving therapy using thulium laser maximal transurethral resection of bladder tumors (TURBT) combined with neoadjuvant therapy and immunotherapy in MIBC patients.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 46 MIBC patients treated with neoadjuvant therapy followed by thulium laser maximal TURBT at a single center between January 2021 and October 2024. Patients had received neoadjuvant immunotherapy in combination with chemotherapy or antibody-drug conjugate before maximal thulium laser TURBT. Those who achieved a complete clinical response were allowed to pursue either bladder preservation or RC. Patients choosing bladder-preserving therapy were either given maintenance immunotherapy or put on observation. Bladder-intact disease-free survival (BIDFS) was assessed through Kaplan-Meier analysis, and Cox regression identified factors influencing BIDFS.</p><p><strong>Results: </strong>Among the 46 patients, 95.7% remained alive, and 82.6% demonstrated no evidence of cancer with bladder function preserved. The estimated 2-year BIDFS rate was 84.2%, and T stage and maintenance immunotherapy were identified as two independent predictors of BIDFS. Patients receiving immunotherapy were at a significantly reduced risk of recurrence compared to their counterparts under observation.</p><p><strong>Conclusion: </strong>Thulium laser maximal TURBT, combined with neoadjuvant therapy and maintenance immunotherapy, is a promising bladder-preserving approach that helps MIBC patients attain favorable BIDFS and quality of life.</p>","PeriodicalId":72421,"journal":{"name":"Bladder (San Francisco, Calif.)","volume":"12 3","pages":"e21200053"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy and limitations of ureteroscopic biopsy in the staging and grading of upper tract urothelial carcinoma: A retrospective analysis at a large tertiary center.","authors":"Tran Ngoc An Huynh, Xinyi Wei, Samiha Arulshankar, James Huang, Nieroshan Rajarubendra, Kevin Chu, Matthew Harper, Scott Donnellan, Weranja Ranasinghe","doi":"10.14440/bladder.2025.0006","DOIUrl":"10.14440/bladder.2025.0006","url":null,"abstract":"<p><strong>Background: </strong>Upper tract urothelial carcinoma (UTUC) poses significant diagnostic challenges due to the limitations of current staging and grading techniques. Ureteroscopic (URS) biopsy is widely used preoperatively, but its accuracy, compared to final pathology, remains variable.</p><p><strong>Objectives: </strong>To evaluate the accuracy and limitations of URS biopsy in the staging and grading of UTUC, using final pathological results from radical nephroureterectomy (RNU) as the reference standard.</p><p><strong>Methods: </strong>This retrospective study included 86 patients who underwent URS biopsy followed by RNU for UTUC at a tertiary institution between 2011 and 2023. Data were collected on patient demographics, tumor characteristics, imaging, and pathology results. The accuracy of URS biopsy in staging and grading was assessed, and its associations with pathological upstaging and non-diagnostic biopsies were statistically analyzed.</p><p><strong>Results: </strong>URS biopsy correctly staged 54.69% of tumors (κ = 0.311 [0.183 - 0.439], p<0.001) and correctly graded 70.93%. (κ = 0.447 [0.303 - 0.592], p<0.001). Pathological upstaging and upgrading occurred in 39.06% and 25.58% of cases, respectively. Non-diagnostic biopsies for both stage and grade were observed in 5.81% of cases, particularly in tumors located in the renal pelvis (p=0.0064). Complementary diagnostic tools, such as computed tomography urography (CTU) and urine cytology, showed limitations, with CTU detecting invasive disease in only 14.29% of cases and urine cytology identifying high-grade tumors in 11.11%.</p><p><strong>Conclusion: </strong>URS biopsy demonstrates limitations in accurately staging and grading UTUC, resulting in a risk of both undertreatment and overtreatment. A multimodal diagnostic approach incorporating imaging, cytology, and clinical judgment is essential to optimizing management decisions and improving oncological outcomes.</p>","PeriodicalId":72421,"journal":{"name":"Bladder (San Francisco, Calif.)","volume":"12 3","pages":"e21200048"},"PeriodicalIF":0.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematuria screening in patients undergoing lung cancer screening.","authors":"Jonathan Maldonado, Johnathan A Drevik, Quinnlyn Walcott, Jacob Adams, Taylor Knowles, Helen Holzbeierlein, George Letner, Jeffrey M Holzbeierlein, Elizabeth Wulff-Burchfield, Eugene K Lee","doi":"10.14440/bladder.2025.0008","DOIUrl":"10.14440/bladder.2025.0008","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer, specifically urothelial carcinoma (UC), poses a significant health concern in the United States and is significantly influenced by tobacco use. Despite its prevalence, routine UC screening is not recommended due to diagnostic limitations and uncertain benefits in long-term survival.</p><p><strong>Objective: </strong>This study examined the effectiveness of urine dipstick screening for UC in subjects already at elevated risk for UC due to substantial smoking histories, who were undergoing low-dose computed tomography (LDCT) for lung cancer screening.</p><p><strong>Methods: </strong>A prospective study was conducted at a single academic center to screen patients undergoing annual LDCT for lung cancer screening for UC. Urine dipstick tests were performed on patients without a history of gross hematuria or previously diagnosed as having UC. Statistical analyses were used to evaluate the relationship between smoking history, urinalysis results, and the prevalence of urological malignancies.</p><p><strong>Results: </strong>We enrolled 201 patients with a mean age of 64.4 years and a balanced gender distribution. Urine dipstick tests detected red blood cells (RBCs) in 15% of patients, with 2.1% showing microhematuria on formal urinalysis (>2 RBC/high power field). Nine (4.5%) participants were advised to undergo comprehensive hematuria evaluations. In addition, four (2%) participants had a history or were newly diagnosed with urological malignancies (three bladder cancer and one kidney cancer).</p><p><strong>Conclusion: </strong>Urine dipstick testing during lung cancer screenings in patients with significant smoking histories may facilitate early detection of urological malignancies, potentially improving patient outcomes. Further research is required to validate these findings, determine cost-effectiveness, and develop standardized screening strategies.</p>","PeriodicalId":72421,"journal":{"name":"Bladder (San Francisco, Calif.)","volume":"12 3","pages":"e21200044"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}